In a large case-control study of Swedish incident type I diabetes patients and controls, 0-34 years of age, we tested the hypothesis that the GIMAP5 gene, a key genetic factor for lymphopenia in spontaneous BioBreeding rat diabetes, is associated with type I diabetes; with islet autoantibodies in incident type I diabetes patients or with age at clinical onset in incident type I diabetes patients. Initial scans of allelic association were followed by more detailed logistic regression modeling that adjusted for known type I diabetes risk factors and potential confounding variables. The single nucleotide polymorphism (SNP) rs6598, located in a polyadenylation signal of GIMAP5, was associated with the presence of significant levels of IA-2 autoantibodies in the type I diabetes patients. Patients with the minor allele A of rs6598 had an increased prevalence of IA-2 autoantibody levels compared to patients without the minor allele (OR ¼ 2.2; Bonferroni-corrected P ¼ 0.003), after adjusting for age at clinical onset (P ¼ 8.0 Â 10 À13 ) and the numbers of HLA-DQ A1*0501-B1*0201 haplotypes (P ¼ 2.4 Â 10 À5 ) and DQ A1*0301-B1*0302 haplotypes (P ¼ 0.002). GIMAP5 polymorphism was not associated with type I diabetes or with GAD65 or insulin autoantibodies, ICA, or age at clinical onset in patients. These data suggest that the GIMAP5 gene is associated with islet autoimmunity in type I diabetes and add to recent findings implicating the same SNP in another autoimmune disease.
Introduction
Type I diabetes is associated with an irreversible autoimmune destruction of the pancreatic islet beta cells. Therefore, patients depend entirely on daily insulin injection replacement therapy to regulate their blood glucose levels. The etiology of type I diabetes is not completely understood, but it is recognized that genetic and environmental factors contribute to development and progression of the disease. 1 The tendency for familial clustering 2 and concordance rates in monozygotic compared to dizygotic twins 1, 3 suggest that genetic factors play a role in etiology. However, the fact that only 10-15% of children diagnosed with type I diabetes have a first degree relative with the disease, 1,4 the low concordance rates in identical diabetic twins 1 and the worldwide increase in type I diabetes incidence in recent years 1, 5 suggest that genetic factors alone do not explain the increased occurrence of type I diabetes.
Environmental exposures triggering type I diabetes in genetically susceptible individuals remain to be established, although it has long been known that type I diabetes may be diagnosed in conjunction with viral infections. 1 Also, maternal enterovirus infections have been shown to increase risk for type I diabetes in their offspring. 1 The association between HLA, the major histocompatibility complex (MHC), and type I diabetes is well established in humans and spontaneously diabetic rodents. 6 From sib-pair analyses, HLA-DR-DQ loci are estimated to confer about 40% 7 of genetic clustering to type I diabetes. Therefore, other susceptibility loci are needed to account for the remainder of genetic risk. 8 Four other genetic factors have been shown to confer risk to type I diabetes: the insulin gene on chromosome 11 (IDDM2 9, 10 ), CTLA-4 on chromosome 2 (IDDM12 11, 12 ), PTPN22 on chromosome 1 13 and ITPR3 on chromosome 6.
14 In addition, several candidate regions have been identified by linkage analysis 15 with different degrees of confirmation. 16, 17 A recent meta-analysis of several independent genome scans conducted by the type I diabetes genetics consortium (TIDGC) confirmed linkage at the HLA locus, chromosome 10, chromosome 16 and chromosome 2. 8 The positional cloning of genetic factors conferring risk is complicated in humans and candidate genes such as the INS VNTR, 9 PTPN22 13 as well as ITPR3 14 were identified in association rather than linkage studies. A recent genome-wide association study 18 in 2000 British type I diabetes patients and 3000 controls identified, apart from HLA, CTLA-4, PTPN22, IL2RA/ CD25 and IFIH1/MDAS but not INS VNTR, five independent association signals at chromosome 12q13, 12q24, 16p13, 4q27 and 12p13. Furthermore, two additional autoimmunity-related associations at 18p11 and 10p15 18 were observed through the combined analysis of autoimmune patients, including those with type I diabetes, indicating that autoimmunity also contributes to type I diabetes risk. It is well known that islet autoimmunity predicts and may precede the clinical onset of type I diabetes by several years. 19 It cannot be excluded that, apart from genetic factors that confer risk for type I diabetes, there are also genetic factors that contribute to islet autoimmunity.
Candidate genes of autoimmune diabetes are also identified in studies of spontaneously nonobese diabetic (NOD) mice 20 and BioBreeding (BB) rats. 21 While MHC class II genes are critical elements to both the NOD 22 and the BB rat, 23 CTLA-4 in the NOD mouse 22 and the lymphopenia gene GIMAP5 in the BB rat 21 are contributing genetic factors.
In BB rats, lymphopenia, which is essential for diabetes, has been shown to be due to a frameshift mutation in the GIMAP5 gene, a member of a multigene family of antiapoptopic genes. 21, 24 In the present study, we investigated whether GIMAP5 (human ortholog of BB rat GIMAP5) affects type I diabetes, by analyzing associations between single nucleotide polymorphisms (SNPs) in the 400 kb region spanning the human GIMAP gene family and outcomes related to type I diabetes, including islet autoantibodies, taking into account potential confounding variables and known risk factors such as HLA-DQ haplotypes.
Results

Selected SNPs
A total of 67 SNPs spanning the human cluster of GIMAP genes were typed. Five SNPs failed the test of HardyWeinberg proportions (HWP) in controls at the 1% level and 11 failed at the 5% level. To be conservative, we removed the 11 SNPs that failed at the 5% level, leaving 56 SNPs for analysis. The positions of these SNPs relative to genes in the GIMAP region are displayed in Figure 1 , along with pairwise measures of their linkage disequilibrium (LD) in control subjects.
Outcome measures
Eight outcome measures were investigated: type I diabetes status (case or control); islet autoantibody positivity in incident type I diabetes patients for autoantibodies (IAA), glutamate decarboxylase (GADA), IA-2A, islet cell antibodies (ICA), very high IA-2A and very high ICA and age at clinical onset in incident type I diabetes patients. The autoantibody cutoff levels used in our analyses are shown in Figure 2 . Autoantibody prevalences in type I diabetes patients were: IAA 35%, GADA 56%, IA-2A 57% and ICA 76%. Very high IA-2A were found in 41% and very high ICA in 9% of patients. Age at onset ranged from 1.1 to 34.8 years, with a mean of 16.9 years.
Analysis strategy
To investigate associations between the 56 SNPs in the GIMAP region and the 8 outcomes, one way to proceed would be to test each of the 56 Â 8 ¼ 448 associations after appropriate adjustment for confounding variables and known risk factors. To make such adjustments, however, detailed statistical modeling would be required for each of the eight outcomes. Therefore, we opted instead for a two-stage strategy in which suggestive unadjusted associations between an outcome and SNPs were identified in an initial screening step. Then, in the second stage, associations between any outcomes and SNPs identified in the first stage were analyzed more carefully by adjusting for confounding variables and known risk factors.
Allelic association scans
The results of allelic association scans are summarized in Table 1 . The strongest evidence for association was found between very high IA-2A and rs6598; the corresponding association profile is shown in Figure 3 , along with the 95% critical value adjusted for multiple testing of SNPs, drawn as a horizontal line. All four of the significantly associated SNPs are in or proximal to the last exon of GIMAP5 and are in high LD with one another (min r 2 ¼ 0.94). There is one SNP in this subregion, rs2286899, that was not in LD with any of the associated SNPs (max r 2 ¼ 0.37) and was not associated with very high IA-2A (adjusted P ¼ 0.98). The remaining SNPs in this subregion are associated with very high IA-2A and form a signal centered at rs6598, the most strongly associated SNP (see Figure 3) . Proceeding in the 5 0 -3 0 direction, one of the associated SNPs (rs1046355) is a synonymous SNP in the coding region of the exon of GIMAP5, two of the associated SNPs (rs10361, rs6598) are in the 3 0 untranslated region (3 0 -UTR) of GIMAP5, and the last of the associated SNPs (rs2286898) is approximately 140 base pairs downstream of the last exon in an intergenic region. The 3 0 -UTR of GIMAP5 has two polyadenylation signals (PAS) listed in the PolyA_DB. The SNP rs6598 is the fifth base of six in the upstream PAS. According to dbSNP (build 127), in non-African populations, the major allele of rs6598 is G and the minor allele is A. Interestingly, the minor allele of rs6598 yields the canonical PAS (AATAAA) associated with approximately 58.2% of polyadenylated expressed sequence tags (ESTs), while the major allele yields a rare PAS (AATAGA) associated with only 0.7% of polyadenylated ESTs. 25 Thus, in the Swedish population, the SNP rs6598 causes a switch from a rare PAS with the major G-allele to the canonical PAS with the minor A-allele.
Detailed association analysis
The only outcome with suggestive associations (Po0.05) was very high IA-2A, with four associated SNPs. From these four SNPs, we chose the most strongly associated, that is rs6598, for detailed analysis. The high pairwise LD between the four SNPs (see Figure 1) suggests that detailed analyses of the associations between very high IA-2A and each of these SNPs would be very similar. Moreover, rs6598 appears to be the most plausible as a functional polymorphism in GIMAP5. We used multiple logistic regression modeling 26 to examine the association between very high IA-2A and rs6598, taking into account potential confounding variables gender and age and HLA-DQ haplotypes, which are known risk factors. For this detailed analysis, we considered 669 type I diabetes patients with information on IA-2A, gender, HLA-DQ haplotypes, age at onset and rs6598 genotypes.
A base logistic regression model relating very high IA-2A to gender, HLA-DQ haplotypes and age at onset, but excluding rs6598, was determined as described in the Supplementary material. The resulting model included terms for HLA-DQ2, HLA-DQ8 and age. The unadjusted frequencies of very high IA-2A support the base model. These frequencies decrease with the number of DQ2 haplotypes: 50% of patients with no DQ2 haplotypes (95% CI [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] , 36% of patients with one DQ2 haplotype (95% CI 31-42) and 9% of patients with two DQ2 haplotypes (95% CI 2-25); and increase with the number of DQ8 haplotypes: 28% of patients with no DQ8 haplotypes (95% CI [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , 46% of patients with one DQ8 haplotype (95% CI 41-51) and 59% of patients with two DQ8 haplotypes (95% CI 45-72). Frequencies are higher in younger than older patients: 50% of 0-to 6-year-olds (95% CI 41-59), 54% of 7-to 13-year-olds (47-60), 40% of 14-to 20-year-olds (33-48), 28% of 21-to 27-year-olds (21-36) and 16% of 28-to 34-year-olds (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Likelihood ratio tests of regression coefficients in the base model confirmed that very high IA-2A were negatively associated with DQ2 (P ¼ 2.5 Â 10
À5
) and age at onset (P ¼ 8.0 Â 10 À13 ), and positively associated with DQ8 (P ¼ 0.002).
Our next step was to add rs6598 to the base model as a predictor of very high IA-2A. To avoid problems with sparse data for A/A genotypes (Table 2) , we combined A/A and G/A genotypes into one category. The final model after forward selection included a term for rs6598 (zero versus one or more copies of the A allele), but no statistical interactions involving rs6598. As shown in Table 2 , the unadjusted frequencies of very high IA-2A were higher in patients with at least one copy of the minor allele A of rs6598. A likelihood ratio test confirmed the association between IA-2A and
). After Bonferroni correction for 56 Â 8 ¼ 448 tests, the association was still significant (P ¼ 0.003). Fitted prevalences of very high IA-2A, by rs6598 genotype group in patients with 0 DQ2 and 1 DQ8 haplotype, are shown in Figure 4 , plotted against age at ( P h y s i c a l L e n g t h : 4 6 9 k b ) r s 6 5 9 8 onset. After controlling for DQ2, DQ8 and age at onset, the odds of very high IA-2A for patients with the minor allele of rs6598 were estimated to be 2.2 times those for patients without the minor allele (Bonferroni-corrected 95% CI 1.1-4.2).
Incorporating prior probability of association In light of an increasing number of nonreplicable association reports, there has been a call to incorporate prior probabilities of association into the determination of significance levels to maintain reasonable rates of true positive findings. 27 Appropriate significance levels for the Bonferroni-corrected P-value were determined using the concept of the false-positive report probability (FPRP), the probability of no true association between a genetic variant and an outcome given a statistically significant finding. 28 We extended the FPRP to multiple testing of associations in a candidate region by defining FPRP M to be the chance that no associations are true given at least one significant finding. As recommended, 28 we selected the significance level so that FPRP M would be less than 50% for all Bonferroni-corrected P-values lower than the level. Since the GIMAP5 homologous region is linked to type I diabetes in the BB rat, we propose a prior probability of association in humans of at least 1/10, but to be conservative we also considered prior probabilities as low as 1/50. To control the FPRP M at 50% with prior probabilities of 1/10, 1/20 and 1/50, the appropriate levels against which to compare the Bonferroni-corrected P-value are 0.034, 0.0121, and 0.0034, respectively. Our P-value of 0.003 is less than all these levels. 
Discussion
Type I diabetes is often viewed as a 'two-step' disease: the first step is to trigger islet autoimmunity. The second step, which may take months to years, is progression from islet autoimmunity to overt hyperglycemia. In the present study, we confirm a lack of association between type I diabetes and GIMAP5. 29 However, we do find that high-level IA-2A are associated with the SNP rs6598 in newly diagnosed patients. Thus, we speculate that this SNP is associated with the first step triggering islet autoimmunity, but not the second step progressing from islet autoimmunity to overt hyperglycemia. Indeed, high-level IA-2A have been reported as the best marker for ensuing hyperglycemia in subjects at risk for type I diabetes. 30 The SNP resides in a PAS of the GIMAP5 gene, with the minor allele (A) leading to the canonical PAS and the major allele (G) leading to a noncanonical PAS. 25 After adjusting for HLA-DQ2 (P ¼ 2.4 Â 10 À5 ) and -DQ8 (P ¼ 0.002) haplotypes, as well as age at onset (P ¼ 8.0 Â 10 Figure 4 Fitted prevalences of very high IA-2A (ICA512) against age at onset by rs6598 genotype grouping in type I diabetes patients with 0 DQ2 and 1 DQ8 haplotype. The effect of rs6598 is significant after adjusting for 56
Association between IA-2A and GIMAP5 J-H Shin et al adjusted association that was observed between very high IA-2A and rs6598 was still significant (P ¼ 0.003).
The SNP rs6598 is in one of two PASs in the 3 0 -UTR of GIMAP5; the PAS in which it resides leads to the shorter transcript. Since both PASs are in the 3 0 -UTR, the short and long transcripts code for the same protein. The SNP rs6598 has recently been implicated in systemic lupus erythematosus. 32 These authors found that variation at this SNP has no effect on transcript levels, but that individuals with one or two copies of the canonical PAS (A) tend to have a higher proportion of the shorter mRNA transcript than individuals homozygous for the noncanonical PAS (G). Therefore, the association that we have observed with very high IA-2A suggests that an increased proportion of the shorter mRNA transcript increases the risk for very high IA-2A. Differential transcript length may affect levels of the translated protein, for example, through differences in stability or translatability of transcripts of different lengths, 33 and has been linked to a variety of diseases such as mantle cell lymphoma. 34 Alternately, rs6598 may have no effect on the risk for very high IA-2A, but rather could be in LD with an unobserved functional polymorphism that does have effect.
GIMAP5 is believed to contribute to T-cell development and survival through apoptosis. Some studies 35, 36 suggest that GIMAP5 is antiapoptotic. However, a recent report 37 has shown that transient overexpression of human GIMAP5 is apoptotic in naive T cells. These authors hypothesize that the apoptotic effect of GIMAP5 depends on the context and factors such as activation status of the T cell, availability of growth factors and the presence of toxic compounds. Given the apparent complexity of the effect of GIMAP5 on T-cell development and survival, it is difficult to speculate on a specific mechanism by which it influences IA-2 autoantibody levels. Over-or underexpression of GIMAP5 may promote apoptosis and death of regulatory T cells that protect from autoimmunity, or may prevent IA-2 autoreactive T cells from dying by apoptosis.
A novel feature of the statistical analysis was our attempt to control the probability that a significant result reflects a true association. Controlling this FPRP 28 has been proposed as a way to reduce the number of nonreplicable association reports for complex genetic disorders. 27 We determined levels of statistical significance taking into account the prior probability of an association with GIMAP5. Since the GIMAP5 homologous region is linked to lymphopenia and type I diabetes in the BB rat, we propose a prior probability of association in humans of at least 1/10. To be conservative, however, prior probabilities as low as 1/50 were considered. For this range of prior probabilities, the chance that the reported association with GIMAP5 is false is below 50%. Hence, the observed association between rs6598 and very high IA-2A in patients is noteworthy.
To our knowledge, this is the first time a genetic factor such as GIMAP5 known to be important to spontaneous diabetes in the BB rat 21, 24 is found to be associated with IA-2A, an islet autoantibody that is strongly associated with type I diabetes risk. Moreover, the association is with high-level IA-2A, reported by others to be the best predictor of the clinical onset of type I diabetes. 30 These authors reported that the HLA-DQ-inferred risk of diabetes may be explained through two distinct pathways distinguished by IA-2A status. Positivity for DQ2/ 8 heterozygosity and IA-2A defined in their study a more homogeneous high-risk population. 30 This is consistent with several reports indicating that the appearance of IA-2A is the best marker for the clinical onset. 38 High-level IA-2A as a particular risk factor now needs to be explored in relation to the GIMAP5 gene and the way the GIMAP5 protein affects T-cell development and survival. 39 The observation that islet autoantibodies are associated with genetic factors that also contribute to the risk for type I diabetes is not novel. We were the first to demonstrate, 31 as later confirmed by others, 40 that the INS VNTR on chromosome 11 is associated with IAA. The association between INS VNTR and IAA is thought to be linked to levels of insulin expressed in the thymus and the ability of individuals to delete self-reactive T cells. Recent studies suggest furthermore that PTPN22 on chromosome 1, which strongly regulates T-cell function, is associated not only with type I diabetes, but also with IAA and progression to disease. 41 The present study as well as those of PTPN22 and INS VNTR therefore underscores the importance of dissecting type I diabetes risk not only with clinical onset as an end point, but also with islet autoantibodies as disease markers. Such an approach may elucidate mechanisms that trigger islet autoimmunity, progression to clinical disease or both. In large, at-risk cohorts such as those of the DPT-1 and ENDIT trials or the longitudinal TEDDY study, it will be of interest to explore the possible role of the PAS polymorphism and other polymorphisms in the GIMAP5 gene in the development of high-level IA-2A.
In conclusion, the present study suggests that the GIMAP5 gene, which contributes to T-cell development and survival, may be associated with an increased risk for the development of high-level IA-2A. The appearance of IA-2A are reported to be associated with clinical onset of type I diabetes and it will be of interest in future studies of individuals with increased HLA genetic risk for type I diabetes to determine the possible importance of the GIMAP5 gene for IA-2A as a marker of subsequent clinical onset.
Research design and methods
Subjects
The current study is based on two Swedish populationbased matched case-control studies described elsewhere. 4, 42 The first study included incident type I diabetes patients who were younger than 15 years and diagnosed anywhere in Sweden between 1 September 1986 and 31 December 1987. In the second case-control study, the incident type I diabetes patients were aged 15-34 years and diagnosed between 1 January 1987 and 31 December 1988. All patients were diagnosed and classified according to the World Health Organization (WHO) criteria. For patients older than 7 years, up to two controls matched by age, gender and geographic region were selected from the Swedish national population registry. For patients aged 7 or less, a matched control treated at the hospital for reasons other than diabetes was selected as described. 4 Since regional systems for the two studies did not coincide, subjects from the study of 0-to 14-year-olds were reassigned to the six regions defined for the study of 15-to 34-year-olds based on the location of the referring hospital. Combination of the studies leads to a total of 1006 incident patients with type I diabetes and 702 control subjects (Table 3 ). For the current investigation of GIMAP5, sufficient DNA was available to genotype 819 of these type I diabetes patients and 595 of the controls.
Genetic markers HLA (IDDM1). HLA typing of DQA1 and DQB1 was performed by PCR amplification of the second exon of the genes followed by dot blot hybridizations of sequence-specific oligo probes and by restriction fragment-length polymorphism using DR-and DQ-based probes to establish haplotypes. 43, 44 HLA-DQ genotypes were already available on 871 of the 1006 patients (87%) and 620 of the 702 control subjects (88%).
GTPase of the immunity-associated protein family member 5 (GIMAP5). Other aliases for GIMAP5 include IAN4, Ian4l1 and Ian5. SNPs spanning the GIMAP family of genes were selected from publicly available SNPs in the dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), HGVbase (http://hgvbase.cgb.ki.se/) and Celera (no longer in existence) databases. SNPs within the approximately 500 kb containing the human cluster of GIMAP genes (Chr7: 149335490-149813248, Golden Path, April 2003) were downloaded into our in-house database SBEAMS-SNP and merged onto a common reference sequence (Golden Path sequence, April 2003). A subset was selected for typing by using the MAGMA algorithm. 45 The SNP selection was optimized to cover the targeted region such that SNPs within genes were prioritized over those in intergenic regions and to select SNPs with higher validation status. A total of 90 SNPs were initially identified by this process and were validated on 32 samples. After validation, 20 SNPs that either were constant or had minor allele frequencies p0.1 in the Swedish population were discarded. Three other failed SNP assays were also discarded. Our aim was to cover all genes in the region and have at least 1 SNP every 10-15 kb for the intergenic regions. We achieved this goal for most intergenic regions.
A total of 67 SNPs covering the GIMAP cluster of genes on human chromosome 7 were genotyped using the MassArray genotyping system (Sequenom Inc., San Diego, CA, USA) as described.
14 In brief, multiplex SNP assays were designed using SpectroDESIGNER software (Sequenom), and 384-well plates containing 5 ng of DNA in each well were amplified by PCR following Sequenom's specifications. Allele discrimination was accomplished through primer extension reactions using the HME chemistry. 46 Following the extension assays, genotypes were determined by spotting 15 nl of each sample onto a 384 SpectroCHIP and reading the chip using the matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer. Mass determination and correlated genotype were determined in real time with MassARRAY RT software. Genotyping failure rates for the 67 SNPs ranged from 3 to 16%; failure rates for the 56 SNPs used in our analyses ranged from 3 to 11%.
Immune markers Insulin antibodies. IAA as well as antibodies to insulin were measured by radiobinding assay using acidcharcoal extraction and cold insulin displacement as described. 47 IAA-D percent measurements were available on 964 of the 1006 patients (96%) and 668 of the 702 control subjects (95%). However, in 210 patients with IAA measurements, sera were sampled 3 weeks after beginning insulin therapy, precluding reliable IAA testing. 42 These patients were therefore excluded from the analysis of IAA. Between 73 and 80% of patients with IAA measurements were genotyped at each of the 56 SNPs considered in our analysis of GIMAP5.
GADA autoantibodies. Antibodies to radiolabeled human Mr 65 000 GADA were quantified by fluid-phase immunoprecipitation assay using fluorographic densitometry as described 48, 49 except that for 15-to 35-year-olds, GAD65 were radiolabeled by coupled in vitro transcription and translation, as described. 50, 51 The two assay formats correlate well, and autoantibody levels are expressed as GADA index, 50 using the WHO-Juvenile Diabetes Foundation (JDF) standard 52 as the positive control. GADA measurements were available on 973 of the 1006 patients (97%) and 682 of the 702 control subjects (97%). Between 72 and 78% of patients with GADA measurements were genotyped at each of the 56 SNPs considered in our analysis of GIMAP5.
Islet antigen-2 (IA-2) or ICA512 autoantibodies. Antibodies to IA-2 (ICA512) 53, 54 were measured by radiobinding immunoassay. 55 The 3 0 portion of the ICA512 cDNA 56 corresponding to the cytoplasmic portion of the protein (residues 602-979) was amplified by RT-PCR from human HTB-14 glioblastoma cells as described. 53 After expression in DH10B Escherichia coli, sequenced plasmid DNA was identical to GenBank sequence L18983. In vitro translation with 35 S-methionine 50 yielded a 46-kDa IA-2 polypeptide highly precipitable by diabetes sera. Radiobinding assays used protein A-Sepharose to separate antibody bound from free IA-2, and autoantibody levels are expressed as an IA-2A index, 50 using the WHO-JDF standard as a positive control. 52 IA-2A measurements were available on 937 of the 1006 patients (93%) and 671 of the 702 control subjects (96%). Between 71 and 78% of patients with IA-2A measurements were genotyped at each of the 56 SNPs considered in our analysis of GIMAP5.
Islet cell (cytoplasmic) antibodies. ICA were determined by indirect two-color immunofluorescence using blood group O frozen human pancreas. 56 The same pancreas was used throughout the study. Coded slides were evaluated by two independent observers. Samples were titered in doubling dilutions to determine end points for conversion into JDF units 57 as described. 56 ICA of 0 JDF units corresponded to no detectable antibody. ICA measurements were available on 1004 of the 1006 patients (99.8%) and 700 of the 702 control subjects (99.7%). Between 71 and 77% of patients with ICA measurements were genotyped at each of the 56 SNPs considered in our analysis of GIMAP5.
Statistical and bioinformatical methods
All statistical analyses were performed in the freely available R statistical computing environment 58 with user-contributed add-on packages. The genetics package 59 was used to test for HWP in controls at level 5%. Patterns of LD in controls were visualized using the LDheatmap package 60 and the r 2 measure. 61 The positions of SNPs were investigated with the UC Santa Cruz Genome Browser 62 using the most recent available reference sequence (NCBI Build 36.1, March 2006). Further information on GIMAP5 poly(A) sites and their signals was obtained from PolyA_DB. 63 Outcome measures. Cutoffs for declaring antibody positivity were determined as described, 31 by examining quantile-quantile (Q-Q) plots of log-transformed antibody measurements in patients and controls. Antibodypositive patients were classified as moderate or very high based on histograms of the log-transformed measurements in patients. If neither Q-Q plots nor histograms suggested distinct subpopulations of antibody-positive individuals, very high antibody status was not determined. The outcome measures considered for analysis were type I diabetes status (case or control); antibody positivity in patients for IAA, GADA, IA-2A, ICA, very high IA-2A and very high ICA and age at onset in patients.
Allelic association scans. Association scans were run for each of the eight outcome measures. Each scan comprised P-values from association tests at 56 SNPs. For type I diabetes and antibody status in patients, each P-value was obtained from a chi-square test of allelic association. For type I diabetes age at clinical onset in patients, the P-value was obtained from a t-test of the regression coefficient in an ordinary linear regression of age onto the number of copies of the minor allele. Each SNP-specific P-value was transformed to reflect the strength of evidence for association by taking the negative base-ten logarithm. For each of the eight outcomes considered, we adopted a permutation approach to adjust for multiple testing of 56 SNPs, since high LD was observed between some pairs of SNPs in the GIMAP region (Figure 2 ). The peak association signal (that is, minimum P-value) over all SNPs was used as the test statistic and its null distribution was estimated from 10 000 permutations of the outcome. The 95% critical value accounting for multiple testing of SNPs, but not for multiple testing of outcomes, is the 5th percentile of this permutation null distribution. A P-value accounting for multiple testing of SNPs is taken as the percentile of this permutation null distribution corresponding to the observed P-value from the association scan. This correction for multiple testing of SNPs will be conservative for all but the minimum P-value observed.
Incorporating the prior probability of association. We extended the concept of the FPRP 28 to multiple testing of associations by defining FPRP M to be the chance that no associations are true given at least one significant finding. To simplify calculations, we made the conservative assumptions of independent association tests and at most a single causal association. The same prior probability of association was assumed for each possible SNP-outcome combination. Under these assumptions, the P-value threshold depends on the prior probability of an association with the genomic region, the specified FPRP M value (for example, 50%) and the average power of the tests. Power to detect associations with type I diabetes was calculated assuming a multiplicative odds model, an odds ratio (OR) of 1.5 and HWP. We used the observed number of patients and controls genotyped at an SNP and the observed minor allele frequency in controls. Power to detect associations with antibody status was similarly calculated based on the numbers of patients with positive antibody status genotyped at an SNP, the observed minor allele frequency in patients with negative antibody status and an OR of 1.5. Power to detect associations with age-at-onset in patients was calculated based on a t-test constructed from the estimated regression coefficient in an ordinary least squares regression of age onto the number of copies of the minor allele, under the alternative hypothesis that the true regression coefficient had a value of 1. 
